Emerging drugs in cutaneous T-cell lymphomas (Q36150634)

12 August 2017

1 reference

title

Emerging drugs in cutaneous T-cell lymphomas (English)

1 reference

12 August 2017

Reinhard Dummer

1

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

Expert Opinion on Emerging Drugs

12 August 2017

published in

1 reference

12 August 2017

volume

10

1 reference

12 August 2017

issue

2

1 reference

12 August 2017

page(s)

381-392

1 reference

Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.381

A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.381

Therapy of cutaneous lymphoma--current practice and future developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.381

Interferon resistance of cutaneous T-cell lymphoma-derived clonal T-helper 2 cells allows selective viral replication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.381

Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.381

Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.381

Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.381

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.381

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.381

Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.381

Immunosuppressive and anti-inflammatory properties of interleukin 10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.381

Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.381

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.381

Topical immunomodulators--progress towards treating inflammation, infection, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.381

Treatment of stage IA cutaneous T-Cell lymphoma with topical application of the immune response modifier imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.381

Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.381

Imiquimod 5% cream in the treatment of mycosis fungoides--a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.381

Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.381

Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.381

Hybrid-cell vaccines for cancer immune therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.381

Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate–pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.381

Topical corticosteroids for mycosis fungoides. Experience in 79 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.381

Narrowband TL-01 phototherapy for patch-stage mycosis fungoides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.381

Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.381

Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.381

Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.381

[Radiotherapy of cutaneous lymphomas]

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.381

Extracorporeal photopheresis in Sézary syndrome. No significant effect in the survival of 44 patients with a peripheral blood T-cell clone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.381

Extracorporeal photopheresis in cutaneous T-cell lymphoma. Inconsistent data underline the need for randomized studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.381

Effectiveness of photopheresis in Sézary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.381

Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.381

Human TH1 and TH2 subsets: regulation of differentiation and role in protection and immunopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.381

Solitary Skin Lesions With Histopathologic Features of Early Mycosis Fungoides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.381

10.1517/14728214.10.2.381

21 January 2018

Identifiers

DOI

1 reference

release_yfbnip5j3zfxrnzr6gxsgi3tae

12 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yfbnip5j3zfxrnzr6gxsgi3tae

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference